CVS
Analysts are basically saying “not bad, CVS”
CVS Health is getting the kind of coverage any stock would happily screenshot for its group chat: 23 analysts, 20 buy ratings, 3 holds, and an average 12-month target sitting around $94.95. That’s not exactly a moonshot parade, but it is a solid “we’re not worried” signal.
The real kicker: the business just flexed
This isn’t happening in a vacuum. CVS also posted a recent quarter that beat expectations, with EPS of $1.09 versus $1.00 expected and revenue of $105.69 billion versus $103.67 billion. Translation: the company isn’t just getting polite analyst nods — it’s also showing the kind of operational numbers that make those nods feel less like hand-waving and more like math.
Why investors should care
The bigger deal is guidance. CVS is now talking about FY2026 EPS of $5.94 to $6.14, while Wall Street was looking for about $5.89. That’s the classic “we have a little more in the tank than you thought” move, which can help support the stock if investors believe the trend is durable.
Big picture: this is less “dramatic breakout” and more “steady, improving picture.” CVS is trying to remind the market it’s still a giant with some horsepower, not just a health-care middleman wearing a pharmacy badge.